Provided by Tiger Trade Technology Pte. Ltd.

Vanda Pharmaceuticals

6.82
-0.1800-2.57%
Post-market: 6.820.00000.00%19:58 EDT
Volume:1.18M
Turnover:8.05M
Market Cap:403.04M
PE:-1.82
High:7.01
Open:6.92
Low:6.73
Close:7.00
52wk High:9.94
52wk Low:3.81
Shares:59.10M
Float Shares:49.48M
Volume Ratio:0.32
T/O Rate:2.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7413
EPS(LYR):-3.7413
ROE:-50.93%
ROA:-16.50%
PB:1.23
PE(LYR):-1.82

Loading ...

Vanda Pharmaceuticals Inc - Secondary Endpoint Met With Tradipitant Reducing Nausea

THOMSON REUTERS
·
Nov 18, 2025

B. Riley Initiates Coverage on Vanda Pharmaceuticals With Buy Rating, $11 Price Target

MT Newswires Live
·
Nov 05, 2025

Vanda Pharmaceuticals Initiated at Buy by B. Riley Securities

Dow Jones
·
Nov 05, 2025

Vanda Pharmaceuticals initiated with a Buy at B. Riley

TIPRANKS
·
Nov 05, 2025

Vanda Pharmaceuticals’ Earnings Call: Growth Amid Challenges

TIPRANKS
·
Oct 31, 2025

Vanda Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Oct 30, 2025

Vanda Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Oct 30, 2025

Vanda Pharmaceuticals Q3 Sales Rise 18% to $56.3 Million

Reuters
·
Oct 30, 2025

BRIEF-Vanda Pharmaceuticals Q3 EPS USD -0.38

Reuters
·
Oct 30, 2025

Vanda Pharmaceuticals Q3 Operating Expenses USD 87.542 Million

THOMSON REUTERS
·
Oct 30, 2025

Vanda Pharmaceuticals Inc Outlook 2025 Total REV $210 Mln to $230 Mln

THOMSON REUTERS
·
Oct 30, 2025

Vanda Pharmaceuticals Advances with Promising Social Anxiety Disorder Treatment Study

TIPRANKS
·
Oct 29, 2025

Vanda Pharmaceuticals Inc expected to post a loss of 45 cents a share - Earnings Preview

Reuters
·
Oct 28, 2025

Vanda Pharmaceuticals Completes Key Bioequivalence Study for Schizophrenia and Bipolar Disorder Treatment

TIPRANKS
·
Oct 28, 2025

Jim Cramer Calls Cameco A Good Company, Recommends Buying This Financial Stock

Benzinga
·
Oct 27, 2025

Vanda Pharmaceuticals Reaches Agreement with FDA

TIPRANKS
·
Oct 02, 2025

Vanda Pharmaceuticals, FDA agree to resolve disputes on Hetlioz and tradipitant

TIPRANKS
·
Oct 02, 2025

BRIEF-Vanda Pharmaceuticals Says FDA To Expedite Re-review Of Tradipitant By Nov 26

Reuters
·
Oct 02, 2025

Vanda Pharmaceuticals and FDA Reach Agreement to Pause Litigation, Expedite Reviews of HETLIOZ® and Tradipitant Disputes

Reuters
·
Oct 02, 2025

Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes With the U.S. Food and Drug Administration

THOMSON REUTERS
·
Oct 02, 2025